Peptide– tag –
-
Samsung Biologics Announces KRW 3 Trillion ($2.18B) Rights Offering to Fund PolyPeptide Group Acquisition and Bio Campus II Expansion, Strengthening CDMO Leadership
PR Newswire South Korea Overview Samsung Biologics has announced a substantial KRW 3 trillion (approximately $2.18 billion) rights offering to finance its acquisition of PolyPeptide Group and the expansion of its Bio Campus II. This stra... -
Eli Lilly’s Oral GLP-1 Agonist ‘Foundayo (orforglipron)’ Receives FDA Approval for Obesity and Overweight Treatment
Drugs.com USA Overview Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist, has received FDA approval for adults with obesity or certain weight-related conditions. This small-molecule, non-peptide GLP-1 receptor... -
New Blood-Brain Barrier Penetration Strategies: Peptides and ‘Trojan Horse’ Approaches Revolutionize Brain Drug Delivery
Facebook USA Overview The blood-brain barrier (BBB) blocks approximately 95% of drugs, severely impeding treatment for brain disorders. Researchers are developing novel techniques to bypass this barrier, including 'Trojan horse' approach... -
Mechano-Piezoelectric F-Peptide Hydrogels Modulate Stem Cell and Immune Niche In Situ, Advancing Cartilage Regeneration
bioRxiv International Overview A new study on bioRxiv reports the development of mechano-piezoelectric F-peptide hydrogels designed for cartilage regeneration. This innovative hydrogel platform uniquely modulates endogenous stem cell and... -
Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout
Samsung Biologics South Korea Overview Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide G... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Rice University Engineers Harness Electrostatic Charge for Weeks-Long Controlled Peptide Release, Revolutionizing Regenerative Medicine
Rice University USA Overview Engineers at Rice University have developed a novel strategy to precisely control the release of therapeutic peptides from gelatin-based materials. By adjusting the peptide's electrical charge, the team signi... -
Beijing Designates Xtalpi and Gan & Lee’s AI Peptide Delivery Lab as Key National Facility for Oral Drug Innovation
Insight, China's Pharmaceutical Industry China Overview The AI Peptide Delivery Lab, a joint venture by Xtalpi and Gan & Lee Pharmaceuticals, has been officially designated a Beijing Key Laboratory, recognizing its cutting-edge R&... -
Peptide Therapeutics: Charting a Course to Oral Delivery Amidst a Surge in FDA Approvals
Stanford Medicine USA Overview The FDA has approved nearly 100 peptide therapeutics for conditions ranging from diabetes to multiple sclerosis, yet most require injection due to their susceptibility to gastrointestinal degradation. A rec... -
Lonza Capsugel Pioneers Dual-Layer Strategy for Oral GLP-1 Delivery, Shielding Peptides from Enzymatic Attack
Capsugel (Lonza) Switzerland Overview Lonza Capsugel has engineered a novel dual-layer protection strategy to enable oral delivery of GLP-1 peptides, circumventing the critical challenge of enzymatic degradation within the gastrointestin...
